Biocytogen, headquartered in Beijing, China, was founded in 2008. Currently, Biocytogen has four branches located in Beijng (Beijing Biocytogen Co.,Ltd), Haimen /Jiangsu  (Biocytogen Jiangsu Co.,Ltd), Shanghai (Biocytogen Shanghai Co.,Ltd) and Wakefield/Boston (Biocytogen Boston Corporation), respectively. With over seven hundred employees worldwide, Biocytogen provides our clients with high quality services, including generation of custom gene-modified animal models/cell lines, animal model breeding and production, preclinical study services focusing on immuno-oncology and therapeutic antibody R&D services. Moreover, our therapeutic antibody R&D service integrates Biocytogen’s novel high throughput hybridoma technology and animal model-based in vivo antibody screening platform. Working closely with our customers, Biocytogen develops therapeutic antibodies against different molecular targets in a fast and cost-effective manner.